<DOC>
	<DOCNO>NCT00483132</DOCNO>
	<brief_summary>Improved outcome high risk lymphoblastic leukemia ( ALL ) laite high dose therapy . High dose versus conventional therapy adult low risk T-ALL Lymphoblastic lymphoma ( LBL ) .</brief_summary>
	<brief_title>Study Treatment High Risk and/or Low Risk Acute Lymphoblastic leuk√©mia ( ALL ) Adults Stage III</brief_title>
	<detailed_description>Comparison two autograf therapeutic strategy high risk patient Ramdomised comparison maintenance treatment interferon alpha 2</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion Criteria ALL high risk low risk lymphoblastic lymphoma age 1555 year old informed consent sign patient previously treat chemotherapy alphainterferon ALL 3 ( burkitt like )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>